Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Obviously 2021 Plans Will Be Presented

<< Previous

Bullboard Posts

Next >>

Comment by Helpmepleaseeeeon Dec 25, 2020 11:18pm

275 Views

Post# 32183247

RE:Obviously 2021 Plans Will Be Presented

Yeah that’s what we are hoping for whatever ever is best for shareholders value and I think partnership would be best considering the pipeline and how positive data is I wouldn’t want to give this company away.......I would want to be rewarded. Pray hard kids

<< Previous

Bullboard Posts

Next >>

Day trading vs. swing trading strategies for small-cap stocks